PetMed Express (NASDAQ:PETS – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect PetMed Express to post earnings of ($0.01) per share and revenue of $59.60 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
PetMed Express (NASDAQ:PETS – Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.17. PetMed Express had a negative net margin of 0.37% and a negative return on equity of 1.00%. The business had revenue of $59.57 million during the quarter, compared to the consensus estimate of $66.02 million. On average, analysts expect PetMed Express to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
PetMed Express Stock Performance
Shares of PETS stock opened at $4.91 on Wednesday. The firm’s 50 day moving average price is $5.09 and its two-hundred day moving average price is $4.28. The stock has a market cap of $101.44 million, a PE ratio of -81.83 and a beta of 0.70. PetMed Express has a 52-week low of $2.90 and a 52-week high of $6.85.
Analyst Ratings Changes
Check Out Our Latest Research Report on PETS
Insider Transactions at PetMed Express
In other PetMed Express news, Director Leslie C.G. Campbell acquired 15,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were acquired at an average price of $5.38 per share, for a total transaction of $80,700.00. Following the acquisition, the director now directly owns 70,000 shares of the company’s stock, valued at approximately $376,600. This trade represents a 27.27 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.10% of the company’s stock.
About PetMed Express
PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Featured Stories
- Five stocks we like better than PetMed Express
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- What Are Dividend Champions? How to Invest in the Champions
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- The How And Why of Investing in Oil Stocks
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.